Related Experiment Video

Updated: May 2, 2026

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

7.9K

The aurora kinases in cell cycle and leukemia

B Goldenson1, J D Crispino1

  • 1Division of Hematology/Oncology, Northwestern University, Chicago, IL, USA.

Oncogene
|March 18, 2014
PubMed

Insights

Aurora kinases are crucial for cell division and are implicated in leukemia. While early inhibitors showed limited success, newer, selective Aurora kinase inhibitors offer promising leukemia treatment strategies.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • Aurora kinases (A, B, and C) are serine/threonine kinases vital for mitosis and meiosis.
  • These kinases are frequently amplified and overexpressed in various cancers, including leukemia.
  • This overexpression suggests Aurora kinases as potential therapeutic targets in leukemia.

Purpose of the Study:

  • To review the functions of Aurora A, B, and C kinases.
  • To summarize the role of Aurora kinases in the development and progression of leukemia.
  • To discuss the development and clinical efficacy of Aurora kinase inhibitors for leukemia treatment.

Main Methods:

  • Literature review of studies on Aurora kinase function, leukemia involvement, and inhibitor development.
  • Analysis of preclinical and clinical trial data for Aurora kinase inhibitors in leukemia.
  • Synthesis of information on kinase biology, cancer mechanisms, and therapeutic strategies.

Main Results:

  • Aurora kinases play essential roles in cell cycle regulation, and their dysregulation is common in leukemia.
  • First-generation Aurora kinase inhibitors demonstrated significant toxicity and limited efficacy.
  • Second-generation inhibitors exhibit improved selectivity and are being investigated for enhanced therapeutic outcomes in leukemia.

Conclusions:

  • Targeting Aurora kinases remains a viable strategy for novel leukemia therapies.
  • Selective Aurora kinase inhibitors show potential for improved efficacy and reduced toxicity in leukemia treatment.
  • Further clinical evaluation of advanced Aurora kinase inhibitors is warranted for leukemia patients.

More Related Videos

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

3.4K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

951

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
8.5K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
2.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K